Is it necessary to prescribe the same dose to subclinical lesions as gross tumor volume in non-small-cell lung cancer? —a failure pattern analysis

Yaner Yu,Yongjie Shui,Xiaofeng Zhou,Lihong Liu,Zhijun Yuan,Qichun Wei
DOI: https://doi.org/10.21203/rs.3.rs-2146660/v1
2022-01-01
Abstract:Abstract Background As the standard practice of our institution, 60Gy is prescribed to PGTV and 54Gy to PTV in the radical radiotherapy of non-small cell lung cancer (NSCLC). We estimate whether this practice could achieve similar tumor control, and protect lymphocyte at the same time. Methods Failure patterns of 46 stage III NSCLC patients received radical radio-chemotherapy were analyzed. Target delineation criterion were as follows: GTV include primary tumor and involved lymph nodes, PGTV expanded from GTV with 5-8mm to compensate for genomic uncertainty. CTV include high-risk area, PTV was extended from CTV with set-up error. 60Gy was prescribed for PGTV, 54Gy for PTV over 30 fractions. The relationship between lymphopenia during radiotherapy and dose-volume parameter was evaluated using Spearman’s correlation analysis. Results With median follow-up of 21.06 months, 22 local-regional recurrence were evidenced, 13 patients have in-field recurrence, one patient failure marginally, and the other 8 patients have out-of field recurrence. Lymphocyte is the most sensitive cell to radiation, lymphopenia during radiotherapy was associated with both PTV(r = 0.489, p = 0.003) and PGTV(r = 0.313, p = 0.076), with larger volume predicted severe lymphopenia. In addition, we observed Lung V(5), V(10) and most of heart or aorta DVH parameters (from V10-V50) are important predictors for lymphocyte nadir. Conclusions Delivered 54Gy to subclinical lesions does not compromise marginal recurrence risk, at the same time lower severe radiation-induced lymphopenia risk. This finding supports further exploration of dosage reduction to CTV in locally advanced NSCLC.
What problem does this paper attempt to address?